Hello rituximab reduces the number of B cells that contain CD20, it reduces the total number of cells that produce antibodies. This may include the antibodies that attach to platelets. There is also evidence that rituximab alters T cells, another type of white blood cell, and that this may be the reason rituximab raises the platelet count of some patients with ITP. The short-term response rate for rituximab is about 60%. About 25% of patients achieve a longer-term (5 year) rise in platelet count.To enhance the response, rituximab is sometimes used in combination with dexamethasone (similar to prednisone) in newly diagnosed patients. So it is not, 100% effective. Please talk to your doctor.